- Home
- LENZ vs DNTH Comparison
LENZ vs DNTH Comparison
Compare LENZ & DNTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LENZ
- DNTH
- Stock Information
- Founded
- LENZ 2019
- DNTH 2015
- Country
- LENZ United States
- DNTH United States
- Employees
- LENZ N/A
- DNTH N/A
- Industry
- LENZ Medicinal Chemicals and Botanical Products
- DNTH Biotechnology: Pharmaceutical Preparations
- Sector
- LENZ Health Care
- DNTH Health Care
- Exchange
- LENZ Nasdaq
- DNTH Nasdaq
- Market Cap
- LENZ 614.9M
- DNTH 711.2M
- IPO Year
- LENZ 2021
- DNTH N/A
- Fundamental
- Price
- LENZ $23.82
- DNTH $21.66
- Analyst Decision
- LENZ Strong Buy
- DNTH Strong Buy
- Analyst Count
- LENZ 6
- DNTH 9
- Target Price
- LENZ $35.40
- DNTH $46.43
- AVG Volume (30 Days)
- LENZ 197.6K
- DNTH 285.9K
- Earning Date
- LENZ 11-06-2024
- DNTH 11-07-2024
- Dividend Yield
- LENZ 30.67%
- DNTH N/A
- EPS Growth
- LENZ N/A
- DNTH N/A
- EPS
- LENZ N/A
- DNTH N/A
- Revenue
- LENZ N/A
- DNTH $5,366,000.00
- Revenue This Year
- LENZ N/A
- DNTH $100.14
- Revenue Next Year
- LENZ N/A
- DNTH N/A
- P/E Ratio
- LENZ N/A
- DNTH N/A
- Revenue Growth
- LENZ N/A
- DNTH 51.41
- 52 Week Low
- LENZ $2.57
- DNTH $14.82
- 52 Week High
- LENZ $38.93
- DNTH $33.77
- Technical
- Relative Strength Index (RSI)
- LENZ 35.08
- DNTH 45.12
- Support Level
- LENZ $21.34
- DNTH $18.72
- Resistance Level
- LENZ $23.84
- DNTH $28.65
- Average True Range (ATR)
- LENZ 1.58
- DNTH 2.31
- MACD
- LENZ -0.39
- DNTH -0.33
- Stochastic Oscillator
- LENZ 25.78
- DNTH 32.14
About LENZ LENZ Therapeutics Inc. Common Stock
LENZ Therapeutics Inc is a late-stage biopharmaceutical company focused on developing and commercializing innovative therapies to improve vision and developing ophthalmic pharmaceutical products.. Its initial focus is the treatment of presbyopia, the inevitable loss of near vision that impacts the daily lives of nearly all people over 45.
About DNTH Dianthus Therapeutics Inc.
Dianthus Therapeutics Inc is a clinical-stage biotechnology company dedicated to designing and delivering novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company is focused on developing next-generation complement therapeutics for patients living with severe autoimmune and inflammatory diseases. The company is comprised of an experienced team of biotech and pharma executives. The company's pipeline consists of DNTH103 a subcutaneous active C1s antibody.